Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 46,966	$ 42,689
Marketable securities available-for-sale	51,009	164,619
Accounts receivable, net	3,552	4,598
Unbilled revenues	1,036	3,002
Inventories	12,018	15,334
Prepaid expenses and other current assets	4,363	3,685
Total current assets	118,944	233,927
Property, plant and equipment, net	26,344	36,080
Investment in Solazyme Bunge JV	35,910	40,934
Other assets	1,225	1,648
Total assets	182,423	312,589
Current liabilities:
Accounts payable	7,016	8,319
Accrued liabilities	14,155	14,079
Current portion of long-term debt	0	6
Deferred revenue	4,159	1,050
Total current liabilities	25,330	23,454
Deferred revenue	500	150
Convertible debt	202,466	200,091
Other liabilities	602	2,518
Total liabilities	$ 228,898	$ 226,213
Commitments and contingencies (Note 12)
Stockholders' equity:
Preferred stock, par value $0.001—5,000,000 shares authorized; 0 shares issued and outstanding	$ 0	$ 0
Common stock, par value $0.001—150,000,000 shares authorized; 81,734,078 and 79,388,069 shares issued and outstanding at December 31, 2015 and 2014, respectively	82	79
Additional paid-in capital	585,679	565,769
Accumulated other comprehensive loss	(22,331)	(11,014)
Accumulated deficit	(609,905)	(468,458)
Total stockholders’ (deficit) equity	(46,475)	86,376
Total liabilities and stockholders’ (deficit) equity	$ 182,423	$ 312,589